콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

E-067

Supelco

Ethosuximide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C7H11NO2
CAS Number:
Molecular Weight:
141.17
EC Number:
UNSPSC 코드:
41116107

Grade

certified reference material

특징

Snap-N-Spike®/Snap-N-Shoot®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

농도

1.0 mg/mL in methanol

형식

single component solution

저장 온도

−20°C

SMILES string

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChI key

HAPOVYFOVVWLRS-UHFFFAOYSA-N

유전자 정보

일반 설명

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

법적 정보

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

픽토그램

FlameSkull and crossbonesHealth hazard

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

표적 기관

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point (°F)

49.5 °F - closed cup

Flash Point (°C)

9.7 °C - closed cup


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Stuart D Greenhill et al.
Neuropharmacology, 62(2), 807-814 (2011-09-29)
Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and
Pue Farooque et al.
Epileptic disorders : international epilepsy journal with videotape, 13(4), 411-416 (2012-01-20)
Childhood absence epilepsy (CAE) typically starts between four and seven years of age. Onset before three years is rare and has not been previously reported from North America. We retrospectively reviewed the electroencephalography laboratory database and paediatric neurology clinic records
Tracy A Glauser et al.
Epilepsia, 54(1), 141-155 (2012-11-22)
Determine the optimal initial monotherapy for children with newly diagnosed childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. A double-blind, randomized controlled clinical trial compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine
Kinga K Borowicz et al.
Annals of agricultural and environmental medicine : AAEM, 19(3), 487-490 (2012-10-02)
Depression is becoming a growing problem in rural areas. This psychiatric disorder often accompanies epilepsy. The aim of this study was to assess the influence of fluoxetine (FXT), a commonly used antidepressant, on the protective action of two conventional antiepileptic
Chinekwu Anyanwu et al.
Journal of child neurology, 28(1), 111-114 (2012-04-03)
Coexistence of 2 idiopathic epilepsy syndromes (ie, childhood absence and Rolandic epilepsy), as evidenced by electroencephalographic (EEG) findings with or without clinical features of the 2 conditions, is uncommon and remains controversial. Few case reports support this coexistence either as

질문

후기

평점 값 없음

활성 필터

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.